Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients with rheumatoid arthritis. Research firm Avance Clinical will manage the trial across up to 10 sites in Australia and New Zealand, overseeing responses from 120 participants as they evaluate how IHL-657A treats patient pain and function over 24 weeks.
Reference article: YouTube
Feb 28, 2023
Cannabis stock Bod Australia (ASX:BDA) has entered the fight against what is known as “long-COVID”. What is ‘long-COVID’? “Long-COVID” ... Read More The post 1 in 10 COVID survivors in Britain still suffer symptoms; ASX cannabis stock Bod wants to help appeared first on Stockhead.
Got 90 seconds? Then listen to Director, Peter Widdows tell us about their company news. Medicinal cannabis and psychedelic therapies ... Read More The post 90 Seconds With…..Peter Widdows, Incannex (ASX:IHL) appeared first on Stockhead.
Special Report: The June quarter demonstrated IHL’s ability to execute on a multi-channel development strategy. ... Read More The post A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy appeared first on Stockhead.